drugset / Trial / NCT01121770
"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine a preventative dose of study drug, Arixtra® for patients with kidney disease. We will measure the blood levels of Arixtra® in patients with kidney disease and develop guidelines for dosing.
Timeline
- Start
- 2010-05
- Primary completion
- 2012-10
- Completion
- 2013-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fondaparinux | Other / unclassified | 1.5 mg | Subcutaneous |